Albert Friesen - Medicure Founder, Chairman and CEO
| MPH Stock | CAD 0.98 0.01 1.01% |
Chairman
Dr. Albert D. Friesen Ph.D. is Chairman of the Board, Chief Executive Officer of the company. and is no longer as President of the company, Effective July 01, 2019. Dr. Friesen holds a Ph.D. in protein chemistry from the University of Manitoba. Dr. Friesen played a key role in founding several health industry companies including Rh Pharmaceuticals, ABI Biotechnology, Viventia Biotech Inc., Genesys Pharma Inc. and KAM Scientific Inc. Dr. Friesen has experience in the establishment of pharmaceutical production facilities and has also managed and initiated the research and clinical development of several pharmaceutical candidates. Dr. Friesen is a founder of the Industrial Biotechnology Association of Canada and past Chairman of its board of directors and former member of the Industrial Advisory Committee to the Biotechnology Research Institute in Montreal. In addition to his role with the Company, Dr. Friesen is currently the President and Chairman of Genesys Venture Inc., a biotech incubator, based in Winnipeg. Dr. Friesen provides his services to the Company through A.D. Friesen Enterprises Ltd., his private consulting corporation.He also served as President until July 25, 2011 at which point that position was filled by Mr. Dawson Reimer. Date of birth is May 19, 1947 since 2019.
| Age | 77 |
| Tenure | 5 years |
| Address | 2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6 |
| Phone | 204 487 7412 |
| Web | https://www.medicure.com |
Medicure Management Efficiency
The company has return on total asset (ROA) of (0.0563) % which means that it has lost $0.0563 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.129) %, meaning that it generated substantial loss on money invested by shareholders. Medicure's management efficiency ratios could be used to measure how well Medicure manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.06 in 2024. Return On Capital Employed is likely to climb to -0.04 in 2024. At this time, Medicure's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 16.1 M in 2024, whereas Other Assets are likely to drop slightly above 62.3 K in 2024.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Abe Schwartz | Covalon Technologies | N/A | |
| Craig Mull | Cipher Pharmaceuticals | N/A | |
| James Gale | Knight Therapeutics | 68 | |
| Amir CFA | Covalon Technologies | N/A | |
| BA LLB | Knight Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0563 |
Medicure Leadership Team
Elected by the shareholders, the Medicure's board of directors comprises two types of representatives: Medicure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicure. The board's role is to monitor Medicure's management team and ensure that shareholders' interests are well served. Medicure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Owens, President COO | ||
| CPA BCom, Chief Officer | ||
| Albert Friesen, Founder, Chairman and CEO | ||
| Jamie Gowryluk, VP Operations | ||
| Reuben Saba, Vice Affairs |
Medicure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medicure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0563 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 6.26 M | ||||
| Shares Outstanding | 10.44 M | ||||
| Shares Owned By Insiders | 26.67 % | ||||
| Shares Owned By Institutions | 23.09 % | ||||
| Number Of Shares Shorted | 2.69 K | ||||
| Price To Earning | 22.88 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medicure Stock Analysis
When running Medicure's price analysis, check to measure Medicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicure is operating at the current time. Most of Medicure's value examination focuses on studying past and present price action to predict the probability of Medicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicure's price. Additionally, you may evaluate how the addition of Medicure to your portfolios can decrease your overall portfolio volatility.